Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI
NCT02787317Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bivalirudin in ischemic heart disease (IHD) (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Creatine Kinase-MB increase at 72 hours. Status: unknown.
02
Drugs
bivalirudin
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT02787317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787317.